Masimo Corporation’s stock is ending the week under pressure, even as the medical-technology company has stacked up several headline catalysts across 2025—from a sweeping strategic reset and long-range financial targets to major legal developments in its long-running dispute with Apple.
As of Friday, Dec. 19, 2025, MASI shares were trading around $132, down roughly 3% on the day after opening near $136 and touching an intraday low near $132, implying a market capitalization of about $7.7 billion.
So what’s going on with Masimo stock right now—and what do current forecasts and recent company updates suggest investors are weighing heading into 2026?
